Double Bond Pharmaceutical International
0.20 SEK
+23.69 %
Less than 1K followers
DBP B
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+23.69 %
+96.10 %
+57.65 %
-21.39 %
-46.41 %
-57.01 %
-54.10 %
-89.67 %
-93.11 %
Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The company's business focus is on the treatment of cancer, infections and autoimmune diseases. The research is based on the company's proprietary drug-delivery technology. The products are sold under separate brands and product development collaborations take place with other players in the industry. The company is headquartered in Uppsala.
Read moreMarket cap
41.36M SEK
Turnover
511K SEK
Revenue
1.09M
EBIT %
-711.93 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27/2
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
DBP: Kommuniké från Extra Bolagsstämma (KBR2) den 12 september 2025 i Double Bond Pharmaceutical International AB (publ)
Rättelse: Mangold Insight har publicerat en fördjupad analys av DBP International AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools